Why Repligen (RGEN) Stock Is Down Today

Repligen Corporation (RGEN) is down 7.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a sector read-through rather than a fresh company-specific setback. A sharp sell-off in a large bioprocessing peer after disappointing commentary on that business line seems to have pressured sentiment across closely related life-sciences tools names, while Repligen is also heading into its own earnings report next week.

Details:

Repligen announced on July 15 that it plans to release second-quarter 2026 results before the market opens on July 28, which can make trading more sensitive to expectation resets.

A major bioprocessing peer dropped sharply on July 21 after investors reacted negatively to bioprocessing timing issues and revenue being pushed into 2027, creating a negative read-through for suppliers exposed to similar end markets.

Repligen’s most recent quarterly update in May included full-year 2026 guidance, so today’s move does not appear tied to a new guidance cut from the company itself.

No obvious new company-specific press release or material SEC filing surfaced alongside the sell-off, so this could be because traders are de-risking ahead of earnings and reacting to weaker peer sentiment.

Sources:

Repligen Investor Relations, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RGEN Insider Trading Activity

$RGEN insiders have traded $RGEN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:

OLIVIER LOEILLOT (Chief Executive Officer) sold 3,832 shares for an estimated $536,480
JASON K GARLAND (CFO) sold 530 shares for an estimated $79,500

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive RGEN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$RGEN Hedge Fund Activity

We have seen 221 institutional investors add shares of $RGEN stock to their portfolio, and 185 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MAVERICK CAPITAL LTD added 1,518,805 shares (+inf%) to their portfolio in Q1 2026, for an estimated $178,945,605
VESTAL POINT CAPITAL, LP added 842,000 shares (+1014.5%) to their portfolio in Q1 2026, for an estimated $99,204,440
MILLENNIUM MANAGEMENT LLC removed 628,085 shares (-96.5%) from their portfolio in Q1 2026, for an estimated $74,000,974
BLACKROCK, INC. removed 626,217 shares (-9.5%) from their portfolio in Q1 2026, for an estimated $73,780,886
MARSHALL WACE, LLP removed 516,336 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $60,834,707
FRED ALGER MANAGEMENT, LLC removed 476,753 shares (-52.3%) from their portfolio in Q1 2026, for an estimated $56,171,038
POINT72 ASSET MANAGEMENT, L.P. removed 436,836 shares (-43.4%) from their portfolio in Q1 2026, for an estimated $51,468,017

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RGEN Analyst Ratings

Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 05/06/2026

To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.

$RGEN Price Targets

Multiple analysts have issued price targets for $RGEN recently. We have seen 12 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.

Here are some recent targets:

Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
Daniel Markowitz from Evercore ISI Group set a target price of $160.0 on 07/06/2026
Sidharth Sahoo from HSBC set a target price of $150.0 on 06/03/2026
Mike Polark from Wolfe Research set a target price of $145.0 on 06/02/2026
Dan Leonard from RBC Capital set a target price of $160.0 on 05/15/2026
Luke Sergott from Barclays set a target price of $160.0 on 05/06/2026
Casey Woodring from JP Morgan set a target price of $165.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.